Total
0
Shares
Sourced: ImpediMed
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • ImpediMed (IPD) has secured a national purchasing agreement with a large U.S. oncology care network for the prevention of lymphedema
  • This agreement gives 1200 physicians at 470 cancer treatment locations across the U.S., access to ImpediMed’s SOZO digital health platform
  • SOZO is a highly-advanced non-invasive bioimpedance spectroscopy device that helps detect and manage patients with secondary lympedema
  • The platform will be used during a Lymphedema Prevention Program
  • This program is aimed at educating health care workers and patients about detecting and managing lymphedema before it becomes serious
  • ImpediMed is trading flat with shares trading for 4.8 cents each

ImpediMed (IPD) has secured a national purchasing agreement with a large U.S. oncology care network for the prevention of lymphedema.

This agreement gives 1200 physicians at 470 cancer treatment locations across the U.S., access to ImpediMed’s SOZO digital health platform through a Lymphedema Prevention Program.

The Lymphedema Prevention Program uses ImpediMed’s Test, Trigger, Treat protocol for early detection of cancer-related lymphedema. Routine lymphedema testing of cancer survivors uses the company’s SOZO device with BIS (LDex) technology.

“This purchasing agreement opens the door to thousands of patients and their care providers to participate in the Lymphoedema Prevention Program,” Managing Director and CEO Richard Carreon said.

The Lymphedema Prevention Program aims to educate healthcare providers and patients that with the right protocols in place, lymphedema can be detected and managed before it becomes a chronic condition.

“We expect SOZO sales in this network to begin immediately and to expand throughout the upcoming year,” Richard added.

ImpediMed received FDA clearance for its SOZO technology in November 2019.

SOZO is a highly-advanced, non-invasive bioimpedance spectroscopy (BIS) device that assesses patients with secondary lymphedema to determine fluid status and tissue composition is less than 30 seconds.

Currently, one in three at-risk cancer survivors will develop secondary lymphedema-related to their cancer treatment. This costs the U.S. healthcare system approximately $7 billion each year.

ImpediMed is trading flat with shares trading for 4.8 cents each at 2:27 pm AEDT.

IPD by the numbers
More From The Market Herald
Race Oncology (ASX:RAC) - CEO, Phillip Lynch

" Race Oncology (ASX:RAC) posts nominal decline in cash

Race Oncology (RAC) has posted a nominal decline in cash and equivalents as of 30 September 2021 to $8.94 million, down from $9.32...
Prescient Therapeutics (ASX:PTX) - Managing Director and CEO, Steven Yatomi Clarke

" Prescient Therapeutics (ASX:PTX) logs timely progress across anti-cancer programs in Q3

Prescient Therapeutics (PTX) says it is poised to reach value-adding milestones across its anti-cancer programs after wrapping up the September quarter with $14.8...
Neuren Pharmaceuticals (ASX:NEU) - CEO, Jon Pilcher

" Neuren Pharmaceuticals (ASX:NEU) highlights trial progress in September quarterly

Neuren Pharmaceuticals (NEU) has released its September quarterly report, highlighting the progress with its upcoming clinical trials.

" Invion (ASX:IVX) sees complete regression of tumours in breast cancer trial

Invion (IVX) shares have soared following its latest trial results, demonstrating a complete regression in tumours following in vivo treatment.